Twist Bioscience's Chief Legal Officer Sold Over 14,000 Company Shares. What Does That Mean for Investors?

1 hour ago 2

Robert Izquierdo, The Motley Fool

Sat, June 6, 2026 astatine 1:39 PM CDT 4 min read

Chief Legal Officer Dennis Cho reported the merchantability of 14,205 shares of Twist Bioscience Corporation (NASDAQ:TWST) connected May 29, 2026, for a transaction worth of astir $991,000, according to a SEC Form 4 filing.

Transaction summary

Metric

Value

Shares sold (direct)

14,205

Transaction value

$991,000

Post-transaction shares (direct)

120,094

Post-transaction worth (direct ownership)

$8.03 million

Transaction worth based connected SEC Form 4 reported terms ($69.75); post-transaction worth based connected holdings arsenic valued utilizing the May 29, 2026 adjacent price.

Key questions

  • How does the size of this merchantability comparison to Dennis Cho’s humanities trading activity?
    This 14,205-share disposition is the largest azygous merchantability executed by Cho successful the past 2 years, astir 12 times the mean sell-only commercialized size of 1,147 shares crossed his 54 merchantability events, and substantially larger than immoderate anterior transaction connected record.

  • What proportionality of Cho’s holdings did this transaction represent, and however does that comparison to caller periods?
    The merchantability accounted for 10.58% of Cho’s nonstop holdings astatine the time, a worldly step-down from 134,299 to 120,094 shares, and contrasts with the smaller incremental income that characterized astir of his trading since January 2025.

  • What is the discourse for the merchantability comparative to caller banal show and capacity?
    As of the May 29, 2026 transaction date, Twist Bioscience shares had appreciated 131.5% implicit the anterior year, and Cho’s remaining nonstop holdings present correspond astir 0.19% of outstanding shares, with ongoing selling cadence reflecting some reduced holdings capableness and sustained stock terms momentum.

Company overview

Metric

Value

Price (as of marketplace adjacent 2026-05-29)

$66.87

Market capitalization

$4.31 billion

Revenue (TTM)

$409.48 million

Net income (TTM)

($81.28 million)

* 1-year show is calculated utilizing May 29th, 2026 arsenic the notation date.

Company snapshot

  • Twist Bioscience offers synthetic DNA products, including genes, illustration mentation tools, antibody libraries for cause discovery, and DNA-based information retention solutions.

  • It generates gross done the merchantability of synthetic DNA-based products and collaborative probe agreements with pharmaceutical and biotechnology partners.

  • The institution serves pharmaceutical companies, biotechnology firms, world probe institutions, and organizations progressive successful diagnostics and cause development.

Twist Bioscience Corporation is simply a starring synthetic biology institution specializing successful high-throughput DNA synthesis utilizing a proprietary silicon-based platform. The institution leverages its exertion to supply scalable, cost-effective synthetic DNA products for research, diagnostics, and therapeutic development.

Read Entire Article